ClinicaliQ Trial Snapshot
- A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors — Recruiting • Phase I / Phase II • NCT06887803.
- Testing whether adding roginolisib to ruxolitinib safely improves outcomes in myelofibrosis patients who haven't responded to JAK inhibitors alone.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis. The main questions it aims to answer is to evaluate the safety and tolerability of roginolisib when administered in combination with ruxolitinib. Conditions: Myelofibrosis (MF) Interventions: Roginolisib Lead Sponsor: iOnctura Planned Enrollment: 26 participants